Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
Rhea-AI Summary
Vera Therapeutics (Nasdaq: VERA) will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas from May 12–14, 2026. Management presentation is scheduled for May 13, 2026 at 4:20 PM PDT, and management will hold one-on-one investor meetings.
A live webcast is available at the provided URL and a replay will be accessible for 90 days via the company’s Investor Calendar. According to the company, the presentation is part of its investor outreach during the conference.
Positive
- None.
Negative
- None.
News Market Reaction – VERA
In the May 4 session, VERA gained 0.88%, reflecting a mild positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 10 | Inducement grants | Neutral | -3.0% | Equity inducement awards to 89 new employees under 2024 Inducement Plan. |
| Mar 27 | Inducement grants | Neutral | -2.0% | Inducement equity awards for newly hired Chief Legal Officer. |
| Mar 25 | Management appointment | Positive | +1.0% | Appointment of Jane Wright-Mitchell as Chief Legal Officer. |
| Mar 06 | Inducement grants | Neutral | -0.3% | Inducement awards to six new employees under 2024 Inducement Plan. |
| Mar 05 | Board appointment | Positive | -2.0% | Appointment of Christopher Hite to Board of Directors. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has focused on governance and inducement equity grants, with generally modest price moves and one notable divergence on a board appointment.
Over the last few months, Vera’s disclosures have centered on management and board additions plus recurring inducement equity grants under its 2024 Inducement Plan. Inducement grant releases on Mar 6, Mar 27, and Apr 10, 2026 saw small negative reactions. Management changes on Mar 5 (new director) and Mar 25 (new Chief Legal Officer) produced mixed outcomes, with one positive and one negative move. Today’s conference-participation news fits into this pattern of non-clinical, corporate updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the Bank of America Securities 2026 Health Care Conference, which is taking place in Las Vegas, NV from May 12-14, 2026. The management team will also participate in one-on-one investor meetings.
Presentation Details:
Date: Wednesday, May 13, 2026
Time: 4:20 PM PDT
Webcast: https://bofa.veracast.com/webcasts/bofa/healthcare2026/24Ty86.cfm
A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
About Vera Therapeutics
Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell–mediated diseases. Vera Therapeutics is also evaluating the development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit www.veratx.com.
Forward-looking Statements
Statements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Vera Therapeutics’ plans, commitments, aspirations and goals related to its product candidates. Words such as “anticipate,” “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics’ business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics' filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
